Table 3.
Subgroup analyses in the 143 cases that developed RA after the questionnaire (incident RA) and their controls
| N (%) | |||
|---|---|---|---|
| Comorbidity | Incident RA (N = 143) | Controls (N = 426) | Unadjusted OR for Incident RA (95% CI)* |
| Rheumatoid arthritis | 33 (26) | 66 (17) | 1.64 (1.01,2.62) |
| HIV | 0 (0) | 4 (1) | - |
| Pulmonary fibrosis | 3 (2) | 5 (1) | 1.74 (0.35,7.21) |
| Rheum. autoimmune dz. | 9 (7) | 18 (4) | 1.56 (0.65,3.47) |
| Autism | 7 (5) | 2 (0.5) | 10.5 (2.51,71.3) |
| Tuberculosis | 5 (4) | 9 (2) | 1.68 (0.51,4.95) |
| Inflammatory bowel disease | 10 (8) | 19 (5) | 1.64 (0.71,3.55) |
| Celiac disease | 10 (8) | 7 (2) | 4.61 (1.73,12.9) |
| Osteoarthritis | 84 (61) | 157 (40) | 2.57 (1.70,3.92) |
| Fibromyalgia | 10 (7) | 29 (7) | 1.03 (0.46,2.10) |
| Hyper/hypothyroidism | 43 (33) | 62 (16) | 2.54 (1.61,4.00) |
| Other liver disease | 16 (12) | 15 (4) | 3.39 (1.62,7.13) |
| Obstructive sleep apnea | 39 (30) | 83 (21) | 1.55 (0.99,2.41) |
| Other mental illness | 17 (13) | 24 (6) | 2.18 (1.12,4.17) |
| Migraine headaches | 45 (34) | 123 (31) | 1.14 (0.74,1.72) |
| Asthma | 43 (32) | 100 (26) | 1.39 (0.90,2.12) |
| COPD | 18 (14) | 51 (13) | 1.03 (0.57,1.81) |
| Venous thromboembolism | 28 (21) | 46 (12) | 1.94 (1.14,3.23) |
| Type 2 diabetes | 42 (32) | 111 (28) | 1.20 (0.78,1.83) |
| Parkinson’s disease | 13 (10) | 25 (7) | 1.58 (0.76,3.14) |
CI = confidence interval, COPD = chronic obstructive pulmonary disease, dz = disease, HIV = human immunodeficiency virus, OR = odds ratio, RA = rheumatoid arthritis, rheum. = rheumatologic
*
Bold values are statistically significant at p<0.01.